Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data.
[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data]. Rev Mal Respir. 2019 Jun 13;: Authors: Debieuvre D, Moreau L, Coudert M, Locher C, Asselain B, Coëtmeur D, Dayen C, Goupil F, Martin F, Brun P, De Faverges G, Hauss PA, Gally S, Ben Hadj Yahia B, Grivaux M Abstract INTRODUCTION: The benefit of tyrosine kinase inhibitors for patients with an EGFR wild-type non-small cell lung cancer (NSCLC) remains controversial. METHODS: The survival of patients with an EGFR wild-type NSCLC who received second- or third-line erlotinib treatment was assessed using real-life data that had been collected in a prospective, national, multicenter, non-interventional cohort study. RESULTS: Data from 274 patients were analysed, 185 (68%) treated with erlotinib and 89 (32%) treated with supportive care only. The median overall survival was 4.2months (95% CI [3.5; 5.4]) with erlotinib, and 1.3months (95% CI [1.0; 1.8]) with supportive care. Survival rate at 3, 6, and 12months was 62%, 37%, and 17%, respectively, with erlotinib, versus 20%, 8%, et 3%, with exclusive supportive care. Significant predictive factors for longer overall survival were the presence of adenocarcinoma, and use of 1st line chemotherapy including either taxanes, pemetrexed or vinorelbine (P
This case report highlights that multidisciplinary treatment planning is critical for stage IIIb –IV non‐small cell lung cancer (NSCLC) patients in the era of highly effective treatments, including chemotherapy, molecular targeted therapy, and immunotherapy, which may demonstrate treatment‐free remission (TFR) even in highly selected advanced lung cancer patients with poly‐metastases, a nd we need more information about the association between each genetic alteration and the significance of salvage surgery. The prognosis of stage IVb non ‐small cell lung cancer (NSCLC) patients with multiple distant metastase...
Conclusions: A cisplatin-HOXB13-ABCG1/EZH2/Slug network may account for a novel mechanism underlying cisplatin resistance and metastasis after chemotherapy. Determining the levels of HOXB13 and its target genes from needle biopsy specimens may help predict the sensitivity of lung adenocarcinoma patients to platinum-based chemotherapy and patient outcomes.
Conclusion and outlookThe case presented here is of interest as it adopts a novel immunotherapeutic approach to HAC, yielding a promising outcome. This highlights the importance of molecular typing and immunohistochemical profiling in the diagnosis and management of non-small cell lung cancer.
CONCLUSION: Patients eligible for chemotherapy rechallenge were those with good prognostic factors. Chemotherapy rechallenge may provide a well-tolerated additional line of treatment, with decreased efficacy compared to its first application. PMID: 31202557 [PubMed - as supplied by publisher]
In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms w...
Conclusions: 18F-MPG PET/CT imaging could accurately reflect the slight active mutant EGFR kinase-expression changes induced by EGFR-TKIsin a noninvasive way and real timeboth in preclinical and clinical. Cisplatin or Pemetrexed exposure resulted a dose-dependent decreasein active mutant EGFR NSCLCs, which this molecular level interfering on EGFR signal pathway can be also detected by 18F-MPGPET/CT imaging. Therefore,compared with 18F-FDG,18F-MPG PET/CT is a reliable tool in monitoring NSCLCs treatments, because of it is not easily affected by inflammation induced by chemotherapy and other factors. It has great potential i...
Conclusions: Baseline MTV based parameters evaluated from primary tumor as well as the whole body tumor lesions are reliable prognostic markers of OS in NSCLC patients. Also, among the post-therapy parameters and percentage changes, whole body MTV based parameters i.e. post-TLGwb and TLGwb can predict OS of NSCLC patients.However, SUV based whole body PET/CT parameters (SUVmax, SUVavg, and TBR) evaluated from baseline as well as post-therapy scans have no prognostic value in these patients.
Conclusions: The ZHER2:V2-pemetrexed conjugates showed promising targeted antitumor activity against HER2-positive lung adenocarcinoma with reduced side effects compared with pemetrexed. ZHER2:V2-pemetrexed is a novel molecular probe with great clinical potential for diagnosis and treatment. Keywords: HER2, affibody, 99mTc-ZHER2:V2-pemetrexed, molecular imaging, therapeutic response. This study was supported by the funds (NO. 81571702) from the National Natural Science Foundation of China project.
Activating mutations in the KRAS oncogene are the most common genetic driver in non-small cell lung cancer (NSCLC), appearing in about 25% of adenocarcinomas and 3% of squamous cell carcinomas [1,2]. Despite their prevalence, the prognostic impact of KRAS mutations remains uncertain. A pooled analysis of phase III clinical trials evaluating adjuvant chemotherapy in early-stage NSCLC determined that KRAS mutations had a negligible impact on overall survival (OS) in patients randomized to observation .
ConclusionsPositive MRI findings suggests heavier disease burden than negative MRI findings in patients with LMC who died of a central nervous system cause. Spinal MRI findings in patients with LMC correlate with cauda equina symptoms.